Cancer researchers are increasingly targeting ferroptosis, a distinct form of programmed cell death driven by iron accumulation and lipid oxidation, as traditional chemotherapy resistance grows. This cellular self-destruction pathway offers a promising alternative when cancer cells develop defenses against conventional treatments. A newly developed nanocomplex called FBR-NDs combines iron ions with immune-stimulating compounds to simultaneously trigger ferroptosis and activate anti-tumor immunity in breast cancer models. The engineered particles respond to the acidic, high-glutathione environment inside tumors by releasing their therapeutic payload specifically where needed. Laboratory testing on aggressive triple-negative breast cancer cell lines BT549 and MDA-MB-231 showed significant growth inhibition through elevated reactive oxygen species and lipid peroxidation—hallmarks of ferroptosis induction. The nanoparticles also disrupted mitochondrial structure and upregulated ferroptosis-related molecular markers. Mouse studies using the 4T1 breast cancer model demonstrated both direct anti-tumor effects and enhanced immune system activation. This dual-action approach represents an evolution beyond single-mechanism treatments that cancer cells often circumvent. Ferroptosis-based therapies may prove especially valuable for treatment-resistant breast cancers, though translating nanomedicine from laboratory to clinic historically faces manufacturing complexity and regulatory hurdles. The iron-dependent mechanism could theoretically be exploited by cancers with altered iron metabolism, and long-term nanoparticle safety remains under investigation. While promising for aggressive breast cancer subtypes, this approach requires validation across diverse patient populations and tumor microenvironments.